120 related articles for article (PubMed ID: 30871916)
1. In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.
Hsieh YY; Liu TP; Yang PM
Pathol Res Pract; 2019 Jun; 215(6):152373. PubMed ID: 30871916
[TBL] [Abstract][Full Text] [Related]
2. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.
Wondergem B; Zhang Z; Huang D; Ong CK; Koeman J; Hof DV; Petillo D; Ooi A; Anema J; Lane B; Kahnoski RJ; Furge KA; Teh BT
Cancer Res; 2012 Sep; 72(17):4361-71. PubMed ID: 22805307
[TBL] [Abstract][Full Text] [Related]
3. High expression of pituitary tumor-transforming gene-1 predicts poor prognosis in clear cell renal cell carcinoma.
Wei C; Yang X; Xi J; Wu W; Yang Z; Wang W; Tang Z; Ying Q; Zhang Y
Mol Clin Oncol; 2015 Mar; 3(2):387-391. PubMed ID: 25798272
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics Analysis Suggests the Combined Expression of AURKB and KIF18B Being an Important Event in the Development of Clear Cell Renal Cell Carcinoma.
Liu Q; Zhang X; Tang H; Liu J; Fu C; Sun M; Zhao L; Wei M; Yu Z; Wang P
Pathol Oncol Res; 2020 Jul; 26(3):1583-1594. PubMed ID: 31489573
[TBL] [Abstract][Full Text] [Related]
5. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
[TBL] [Abstract][Full Text] [Related]
6. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
7. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
[TBL] [Abstract][Full Text] [Related]
8. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
9. The clinical value and biological function of PTTG1 in colorectal cancer.
Ren Q; Jin B
Biomed Pharmacother; 2017 May; 89():108-115. PubMed ID: 28219049
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma.
Hansson J; Lindgren D; Nilsson H; Johansson E; Johansson M; Gustavsson L; Axelson H
Clin Cancer Res; 2017 Apr; 23(8):2105-2115. PubMed ID: 27663598
[No Abstract] [Full Text] [Related]
11. Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Zhang J; Zhang J; Lin Z
BMC Cancer; 2019 Jul; 19(1):698. PubMed ID: 31311512
[TBL] [Abstract][Full Text] [Related]
12. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
[TBL] [Abstract][Full Text] [Related]
13. Exploring the mechanism of clear cell renal cell carcinoma metastasis and key genes based on multi-tool joint analysis.
Yang H; Li W; Lv Y; Fan Q; Mao X; Long T; Xie L; Dong C; Yang R; Zhang H
Gene; 2019 Dec; 720():144103. PubMed ID: 31491435
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
15. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
Li JD; Farah AA; Huang ZG; Zhai GQ; Wang RG; Liu JL; Wang QJ; Zhang GL; Lei ZL; Dang YW; Li SH
BMC Cancer; 2022 Jun; 22(1):713. PubMed ID: 35768832
[TBL] [Abstract][Full Text] [Related]
17. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.
Castilla C; Flores ML; Medina R; Pérez-Valderrama B; Romero F; Tortolero M; Japón MA; Sáez C
Mol Cancer Ther; 2014 Oct; 13(10):2372-83. PubMed ID: 25122070
[TBL] [Abstract][Full Text] [Related]
19. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
Zhou L; Liu S; Li X; Yin M; Li S; Long H
Mol Med Rep; 2019 May; 19(5):3485-3496. PubMed ID: 30896867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
